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ABSTRACT 
The aim of the present meta-analysis was to find out the impact of MIF -173 G > C polymorphism on risk of 
tuberculosis (TB). We conducted a search of case–control studies on the associations of -173 G > C variant of MIF 
with susceptibility to tuberculosis in PubMed, ISI Web of Science, and Scopus. We extracted the data from eligible 
studies and achieved a meta-analysis to examine the relationship between MIF -173 G > C polymorphism and the 
risk of TB. Odds ratios (ORs) with the corresponding 95 % confidence intervals (CIs) were pooled to find out the 
impact of MIF -173G > C promoter polymorphism on TB risk. The pooled ORs were calculated for the codomi-
nant, dominant, recessive, and allelic model comparison. The findings revealed that MIF -173 G > C variant in-
creased the risk of TB in codominant (OR = 1.54, 95 %CI = 1.26-1.88, p < 0.0001; CG vs GG), and dominant 
(OR = 1.62, 95 %CI = 1.33-1.96, p < 0.00001; GC+CC vs GG) inheritance models tested. The results suggested 
that the MIF -173 C allele significantly increased the risk of PTB (OR = 1.49, 95 %CI = 1.28-1.74, p < 0.00001). 
The findings of this meta-analysis propose that MIF -173 G > C variant is associated with the risk of TB. More 
case-control studies with well-designed in different ethnic groups and larger sample size are needed to confirm the 
findings.  
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INTRODUCTION 
Tuberculosis (TB), mainly caused by My-
cobacterium tuberculosis (M. tuberculosis), is 
a main global public health problem and it is 
responsible for high mortality and morbidity 
worldwide particularly in Asia and Africa 
(Zaman, 2010). World Health Organization 
(WHO) report proposed that nearly 9 million 
subjects developed TB in 2014 and 1.5 mil-
lion people died from the disease (Zumla et 
al., 2015). Though one third of the world’s 
population has infected latent TB, merely 5–
10 % of infected cases will develop the clini-
cal disease (Philips and Ernst, 2012).  
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Previous studies in animals and humans 
have shown that, apart from environmental 
factors, genetic background of the host may 
play an important role in the development of 
TB (Bellamy, 2003; Schurr, 2007; Azad et al., 
2012; Meilang et al., 2012; Tong et al., 
2015a). Until now, several gene polymor-
phisms have been suggested as being associ-
ated with susceptibility to TB (Hashemi et al., 
2013; Naderi et al., 2014a, b; Yang et al., 
2016).  
Human macrophage migration inhibitory 
factor (MIF) gene is located on long arm of 
chromosome 22 (22q11.2). The gene consists 
of three exons of 205, 173 and 183 bp sepa-
rated by two introns of 189 and 95 bp (Budarf 
et al., 1997). A -173 G > C functional variant 
in the promoter region of MIF seems to affect 
promoter activity in a cell-type dependent 
manner (Donn et al., 2002; Renner et al., 
2005). MIF protein is a multifunctional cyto-
kine that is made by many types of cells such 
as epithelial cells as well as cells contribute to 
the innate and adaptive immune responses 
(Calandra et al., 1994; Bacher et al., 1997). 
MIF is known as an immunomodulatory cyto-
kine that involved in the initiation of innate 
immune response by inducing tumor necrosis 
factor-α (TNF-α), Interferon-γ (IFN-γ), inter-
leukin-2 (IL-2), and IL-6 production during 
microbial infection (Calandra et al., 1995; 
Roggero et al., 2002; 2004; Marinho et al., 
2007).  
Several studies investigated the impact of 
MIF -173 G > C variant on risk of tuberculo-
sis (Gomez et al., 2007; Sadki et al., 2010; Li 
et al., 2012; Hashemi et al., 2013; Kuai et al., 
2016; Liu et al., 2016). The present study 
aimed to perform a meta-analysis of all eligi-
ble studies to evaluate the overall association 
between the MIF -173 G > C polymorphism 
and risk of tuberculosis.  
 
METHODS 
A comprehensive search of PubMed, Web 
of Science, Scopus, and Google Scholar was 
done from database for articles published up 
to April 04, 2016 without language re-
striction. The search strategy was “macro-
phage migration inhibitory factor or MIF” and 
“polymorphism or variant or mutation or gen-
otype” and tuberculosis. Relevant studies 
which were eligible for the meta-analysis 
must meet the following criteria: studies were 
included in this meta-analysis if the met the 
following criteria: 1) case-control studies of 
the correlation between the -173 G > A vari-
ant of MIF gene and tuberculosis; 2) studies 
enrolled more than 30 patients;  
3) studies provided the genotype frequencies 
of MIF -173 G > A polymorphism in both 
cases and controls. Figure 1 summarized the 
process of identifying eligible studies. 
 
 
Figure 1: Flow chart of literature screening and 
selection in the meta-analysis 
 
 
Data extraction 
Extraction of the data was done by two in-
dependently authors. The following data were 
collected from each study including the first 
author’s name, publication year, ethnicity of 
participants, genotyping methods of  
-176 G > C polymorphism, the sample size, 
and the genotype frequencies of the variant in 
both cases and controls. 
 
Statistical analysis 
We performed the present meta-analysis 
using RevMan 5.0 software which was pro-
vided by the Cochrane Collaboration (Ver-
sion 5.3. Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2014). 
All of the data in the studies are dichotomous 
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data expressed as odds ratios (ORs) with 95 % 
confidence intervals (CIs) to assess the asso-
ciation between MIF -137 G > C gene poly-
morphism and TB. Hardy–Weinberg equilib-
rium (HWE) for each study was determined 
by the chi-square test.  
Statistical heterogeneity among the stud-
ies was evaluated using the Q-test and I2-test. 
The pooled ORs were calculated using the 
fixed-effect inverse variance analysis method 
or random-effect model (when heterogeneity 
among the studies was observed) for the al-
lelic comparison (C v G) and genotypic com-
parisons of codominant (CG vs GG and CC 
vs GG), dominant (CG +CC vs GG), and re-
cessive (CC vs CG+GG) genetic inheritance 
models. The significance of the pooled OR 
was assessed by the Z-test, and P < 0.05 was 
considered to be statistically significant. Pub-
lication bias was estimated by funnel plot.  
 
RESULTS 
After our selection, five case–control 
studies satisfied the inclusion criteria for our 
meta-analysis (Gomez et al., 2007; Sadki et 
al., 2010; Li et al., 2012; Hashemi et al., 2015; 
Liu et al., 2016). Characteristics of included 
studies are summarized in Table 1.  
Five studies involving 929 cases and 876 
controls were pooled together for assessment 
of the overall association between MIF -173 
G > C variant and the risk of tuberculosis. As 
shown in Figure 2, the finding proposed that 
the MIF -173 C allele significantly increased 
the risk of PTB (OR = 1.49, 95 %CI = 1.28-
1.74, p < 0.00001). Furthermore, the MIF  
-173 G > C variant increased the risk of TB in 
codominant (OR = 1.54, 95 %CI = 1.26-1.88, 
p < 0.0001; CG vs GG), and dominant 
(OR = 1.62, 95 %CI = 1.33-1.96, 
p < 0.00001; GC+CC vs GG) inheritance 
models tested. But the variant was not associ-
ated with TB in recessive inheritance model 
(OR = 1.46, 95 %CI = 0.73-2.93, p = 0.290; 
CC vs GC+GG).  
A funnel plot was generated as a visual aid 
to detect risk of publication bias (Figure 3). 
 
DISCUSSION 
In the current meta-analysis, we summa-
rized all of the available data regarding the as-
sociation between MIF -173 G > C variant 
and TB risk. Our findings indicated that MIF 
-173 G > C polymorphism significantly in-
creased the risk of TB susceptibility in co-
dominant, dominant and allelic models.  
MIF plays important functions in regula-
tion of inflammation and innate immune re-
sponse. Interestingly, MIF signaling path-
way counteracts glucocorticoids regulatory 
effects in immune system. (Xu et al., 2013). 
Several studies proposed that MIF polymor-
phism increased the risk of immune disease. 
Liu et al. (2014) revealed that MIF rs755622 
polymorphism may be a risk factor for new-
onset Graves’ disease in a Taiwanese Chinese 
population.  
A meta-analysis performed by Hao et al 
(Hao et al., 2013) showed that MIF -173 
G > C polymorphism contributed to the sus-
ceptibility of inflammatory bowel disease 
(IBD). In contrast, the findings of a meta-
analysis performed by Falvey et al. (2013) did 
not support an association between MIF -173 
G > C polymorphism and susceptibility to 
IBD in Caucasian subjects. 
Zhang et al. (2015) carried out a meta-
analysis to find out the impact of MIF -173 
G > C polymorphism and cancer risk. They 
found that this variant was significant associ-
ated with cancer risk. The findings of another 
meta-analysis proposed that MIF -173 G/C 
gene polymorphism would be a risk factor for 
the gastrointestinal cancer and hematological 
malignancy (Tong et al., 2015c). 
It has been shown that MIF -173 G > C 
gene polymorphism may be associated with 
renal disease susceptibility, particularly in 
children. Moreover, the findings of a meta-
analysis designated that this variant may be 
related to glucocorticoid resistance in child 
patients with idiopathic nephrotic syndrome 
(Tong et al., 2015b). A meta-analysis per-
formed by (Kaalla et al., 2013) showed that 
MIF -173 G > C variant was not associated 
with juvenile idiopathic arthritis. 
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Table 1: Baseline characteristics of all included study 
References Year Coun-try Ethnicity 
Genotyp-
ing meth-
ods 
Genotype Allele 
HWE 
test cases controls cases controls 
GG GC CC total GG GC CC total G C total G C total
Gomez et 
al., 2007 2007
Co-
lombia 
Latin-
Ameri-
can 
Taqman 120 95 15 230 133 86 16 235 335 125 460 352 118 470 yes 
Hashemi et 
al., 2015 2015 Iran Asian 
PCR-RFLP
  99 53 9 161 105 32 5 142 251 71 322 242 42 284 yes 
Li et al., 
2012 2012 China Asian 
PCR-
RFLP  109 74 32 215 168 61 16 245 292 138 430 397 93 490 no 
Liu et al., 
2016 2016 China Asian 
PCR-
RFLP  80 116 4 200 57 37 6 100 276 124 400 151 49 200 yes 
Sadki et al., 
2010 2010
Mo-
rocco African TaqMan 57 45 21 123 82 63 9 154 159 87 246 227 81 308 yes 
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Figure 2: Forest plot of tuberculosis risk associated with MIF -173 G > C polymorphism. 2A. Allelic 
model (C vs G). 2B. Codominant model (CG vs GG). 2C. Codominant model (CC vs GG). 2D. Dominant 
model (CG+CC vs GG). 2E. Recessive model (CC vs CG+GG). The squares and horizontal lines cor-
respond to the study-specific OR and 95 % CI, respectively. The area of the squares reflects the study-
specific weight. The diamond represents the pooled results of OR and 95 % CI.  
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Figure 3: Funnel plots in the meta-analysis of the association between MIF -173 G > C polymorphism 
and tuberculosis risk. 3A. Allelic model (C vs G). 3B. Codominant model (CG vs GG). 3C. Codominant 
model (CC vs GG). 3D. Dominant model (CG+CC vs GG). 3E. Recessive model (CC vs CG+GG). 
 
 
There are several limitations of the current 
meta-analysis. First, only published data were 
entered in a few databases, consequently a 
publication bias may have happened. Second, 
the predisposition to TB is complex and in 
most cases does not depend on a single gene 
polymorphism, but somewhat on many gene 
variants or gene-environment interaction.  
In conclusion, the findings of this meta-
analysis support an association between MIF 
-173 G > C variant and risk of TB. 
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